| Title : Managing Alzheimer dementia tomorrow - Rosenthal_2003_J.Am.Board.Fam.Pract_16_423 |
| Author(s) : Rosenthal TC , Khotianov N |
| Ref : J Am Board Fam Pract , 16 :423 , 2003 |
| Abstract : BACKGROUND: Acetylcholinesterase inhibitors are the first drugs to alter the devastating effects of Alzheimer disease. The next generation of drugs will prevent the beta-amyloid plaques and neurofibrillary tangles or block enzymes that lead to neuron destruction. Effective use of these medications will require early identification of patients at risk. METHODS: Using the PubMed service of the National Library of Medicine, all English language articles published in 2000, 2001 and the first half of 2002 with a key word of 'dementia' were reviewed for articles that described the emerging pathophysiologic model for Alzheimer disease. FINDINGS: Standardized clinical screening tools, such as the mini-mental status examination and the clock test, administered longitudinally and correlated with family observations, can identify many at-risk patients. Genetic testing can identify a known mutation in 70% of patients who have a high family incidence of Alzheimer disease but awaits effective prevention before being useful. The molecular mechanisms of Alzheimer disease will eventually lead to prevention. CONCLUSION: Today, these patients benefit from nutritional support and lifestyle enhancement encouraged through a continuous primary care relationship. |
| ESTHER : Rosenthal_2003_J.Am.Board.Fam.Pract_16_423 |
| PubMedSearch : Rosenthal_2003_J.Am.Board.Fam.Pract_16_423 |
| PubMedID: 14645333 |
Rosenthal TC, Khotianov N (2003)
Managing Alzheimer dementia tomorrow
J Am Board Fam Pract
16 :423
Rosenthal TC, Khotianov N (2003)
J Am Board Fam Pract
16 :423